RxDoctor Payments Data

Alyssa Brion, PA

Physician Assistant · Irving, TXNPI 1356943013

Payments from drug & device makers

$971in general payments, 2019–2025

Across 50 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$309
  • Lilly USA, LLC$238
  • AstraZeneca$49
  • Amarin Pharma, Inc.$45
  • AbbVie$44
  • Takeda Pharmaceuticals U.S.A., Inc.$42
  • plus $244 from 11 others

What the payments were for

  • Food & beverage$971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$971 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$36,405
Medicare patients
120
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$44,555
OzempicSemaglutide11$28,388
EliquisApixaban19$18,515
SymbicortBudesonide/Formoterol Fumarate21$6,633
Gabapentin79$3,163
Armour ThyroidThyroid,pork11$1,392
Venlafaxine Hcl ErVenlafaxine Hcl20$1,104
Levothyroxine Sodium119$1,092
Rosuvastatin Calcium92$1,070
Losartan Potassium122$1,066
Atorvastatin Calcium138$1,061
Albuterol Sulfate HfaAlbuterol Sulfate44$1,013
Duloxetine Hcl31$941
Metformin Hcl96$922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$44,55539 claims
Novo NordiskOzempic$309$28,38811 claims
PfizerEliquis$20$18,51519 claims
AstraZenecaSymbicort$49$6,63321 claims
AbbVieArmour Thyroid$44$1,39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →